@article{PAR00011502,
  title = {{S}erum concentration of co-trimoxazole during a high-dosage regimen},
  author = {{A}meen, {S}. {M}. and {R}olain, {J}. {M}. and {L}e {P}oullain, {M}. {N}. and {R}oux, {V}. and {R}aoult, {D}idier and {D}rancourt, {M}.},
  editor = {},
  language = {{ENG}},
  abstract = {{O}bjectives: {S}ulfamethoxazole and trimethoprim have been used for decades, yet high dosages are rarely reported. {W}e aimed to measure blood concentrations of both molecules in this situation. {M}ethods: {B}etween 2002 and 2010, 22 patients received two tablets of co-trimoxazole three times a day, equivalent to a daily dosage of 2400 mg of sulfamethoxazole and 480 mg of trimethoprim. {T}he trimethoprim and sulfamethoxazole concentrations were determined 3 h after administration using ion-paired {HPLC}. {R}esults: {I}n the presence of a negative control, which yielded no peaks at the retention times for trimethoprim and sulfamethoxazole, the mean +/- {SD} value for sulfamethoxazole concentration was 161.01 +/- 69.154 mg/{L} and the mean +/- {SD} value for trimethoprim was 5.788 +/- 2.74 mg/{L}. {C}onclusions: {T}hese concentrations are largely above the trimethoprim and sulfamethoxazole {MIC} distributions as well as the trimethoprim resistance clinical breakpoint (4 mg/{L}) reported by {EUCAST} in 2012 for most bacterial pathogens, including {G}ram-positive species such as {S}taphylococcus aureus. {O}ur results support proposing a high-dosage regimen of co-trimoxazole as a suitable alternative for methicillin-resistant {S}. aureus infections.},
  keywords = {sulfamethoxazole ; trimethoprim ; {MRSA}},
  booktitle = {},
  journal = {{J}ournal of {A}ntimicrobial {C}hemotherapy},
  volume = {69},
  numero = {3},
  pages = {757--760},
  ISSN = {0305-7453},
  year = {2014},
  DOI = {10.1093/jac/dkt400},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00011502},
}